Form 4: Provectus Biopharmaceuticals CEO Converts Promissory Note to Preferred Stock

CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock on April 29, 2025.

Summary

• On April 29, 2025, Edward Pershing, CEO of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into 18,876 shares of Series D-1 Convertible Preferred Stock.
• The conversion price was $2.862 per share.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the company's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• Following the transaction, Pershing directly owns 2,091,852 shares of Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (conversion of debt to equity) and doesn't necessarily indicate positive or negative outlook for the company.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

This filing reflects insider activity related to the conversion of debt into equity, which is a common financial maneuver for companies, especially in the biotechnology sector. It can be seen as a sign of confidence from the CEO, but also impacts the company's capital structure.

Stakeholder Impact

• The conversion of preferred stock to common stock could dilute existing shareholders' equity.

Key Dates

Keywords

Form 4, Beneficial Ownership, Series D-1 Convertible Preferred Stock, Convertible Promissory Note, Edward Pershing, Provectus Biopharmaceuticals, PVCT, Conversion